During immunosuppression, cytomegalovirus (CMV) can reactivate and cause serious clinical problems. Normally, abundant virus replication is suppressed by immune effector mechanisms. To study the interaction between CD8$^+$ T cells and persisting viruses, frequencies and phenotypes of CMV-specific CD8$^+$ T cells were determined in healthy individuals and compared to those in renal transplant recipients. In healthy donors, function of circulating virus-specific CD8$^+$ T cells, as measured by peptide-induced interferon-$\gamma$ (IFN-$\gamma$) production, but not the number of virus-specific T cells enumerated by binding of specific tetrameric peptide/HLA complexes, correlated with the number of CMV-specific IFN-$\gamma$-secreting CD4$^+$ helper T cells. Circulating CMV-specific CD8$^+$ T cells did not express CCR7 and may therefore not be able to recirculate through peripheral lymph nodes. Based on coexpression of CD27 and CD45R0 most CMV-specific T cells in healthy donors appeared to be memory-type cells. Remarkably, frequencies of CMV-specific CD8$^+$ T cells were significantly higher in immunosuppressed individuals than in healthy donors. In these patients CMV-specific cells predominantly had an effector phenotype, that is, CD45R0$^-$CD27$^-$CCR7$^-$ or CD45RA$^+$CD27$^-$CCR7$^-$ and contained both granzyme B and perforin. Our data show that in response to immunosuppressive medication quantitative and qualitative changes occur in the CD8$^+$ T-cell compartment. These adaptations may be instrumental to maintain CMV latency. (Blood. 2001;98:754-761)

© 2001 by The American Society of Hematology

Introduction

The immunologic control of persistent viral infections, like infections with the family of herpes viruses, requires the coordinated actions of many cell types. CD4$^+$ T cells appear to play a key role in this process because they orchestrate the various effector arms of the immune system. In mice it has been shown that the production of neutralizing antibodies to many viruses critically depends on the availability of specific CD4$^+$ helper T cells. In line with this, we recently demonstrated that in primary human cytomegalovirus (CMV) infection the emergence of helper T cells precedes the appearance of virus-specific antibodies. CD8$^+$ T cells eliminate virus-infected cells and are thought to be the major effector cells in controlling persistent infection. In many instances, differentiation of CD8$^+$ T cells into competent effector cells depends on the presence of helper CD4$^+$ T cells.

On encountering viruses, CD8$^+$ T cells can differentiate from naive T cells into effector T cells that through cytolysis and secretion of specific cytokines control virus replication and into memory cells that provide enhanced immunity after renewed contact with the same pathogen. To study the development of these cells in clinically relevant situations in humans, various phenotypic markers have been used that allow separation of the aforementioned subsets. Naive CD8$^+$ T cells express CD45RA and CD62L and also the costimulatory receptors CD27 and CD28, whereas memory-type cells express CD45R0, CD27, and CD28 molecules and low levels of CD62L. Effector-type cells have a CD45RA$^-$CD27$^-$CD28$^-$ phenotype and contain perforin, granzyme B, and CD95 ligand to directly execute cytolysis. More recently, Sallusto and coworkers separated subsets of peripheral blood CD4$^+$ and CD8$^+$ T cells based on the expression of CCR7, which binds secondary lymphoid chemokine (SLC) and macrophage inflammatory protein 3$\gamma$ (MIP-3$\gamma$), chemokines that direct migration of lymphocytes to secondary lymphoid organs. CD8$^+$CCR7$^-$CD45RA$^+$ T cells, designated central memory cells (T CM), have the potential to migrate to peripheral lymph nodes and do not directly produce cytokines after in vitro stimulation. Effector memory cells (T EM) do not express CCR7 and have perforin-containing granules and may directly exert effector functions in peripheral tissues. It thus appears that the regulation of CD27 and CCR7 is concordant in CD8$^+$ T cells, but this has not yet been directly addressed.

Human CMV is a persistent $\beta$-herpesvirus that is present in approximately 50% of the adult population. Latent infection is asymptomatic in healthy individuals but can cause serious disease in immunocompromised individuals. Severely impaired T-cell function leads to viral reactivation and morbidity due to cytotoxic effects of uncontrolled viral replication, and CMV reactivation coincides with higher levels of immunosuppressive therapy. Interestingly, however, most renal transplant recipients who receive...
Immunofluorescent staining and flow cytometry

For the longitudinal study, 6 HLA-A2+, CMV-seropositive renal transplant recipients were selected. Heparinized peripheral blood samples were collected before transplantation and 12 months after transplantation. Periperal blood mononuclear cells (PBMCs) were isolated using standard density gradient centrifugation techniques as described by Rentenaar and coworkers.11 In brief, purified HLA-A2.1 heavy chain and tetrameric complexes were generated essentially as described by Altman and coworkers.12 Generation of HLA-A2.1/CMVpp65(NLVPVMATV) tetrameric complexes

Tetrameric complexes were generated essentially as described by Altman and coworkers.11 In brief, purified HLA-A2.1-heavy chain and β₂-microglobulin was synthesized using a prokaryotic expression system (pET; Novagen, Milwaukee, WI). The heavy chain was modified by deletion of the transmembrane/cytosolic tail and COOH-terminal addition of a sequence containing the BirA enzymatic biotinylation site. The HLA-A2.1–binding CMVpp65-derived peptide NLVPVMATV (single-letter amino acid codes) was used for refolding. The refolded product was isolated using high-performance liquid chromatography (HPLC), biotinylated by BirA (expressed using the pET expression system, purified using Clontech cobalt beads, Palo Alto, CA) in the presence of biotin (Molecular Probes, Eugene, OR), adenosine triphosphate (ATP; Sigma Chemical, St Louis, MO), and MgCl₂. The biotinylated product was separated from free biotin by gel filtration using HPLC.12 Streptavidin–phycoerythrin (PE) or streptavidin–allophycocyanin (APC) conjugate (Molecular Probes) was added in a 1:4 molar ratio.

### Table 1. Characteristics of subjects

<table>
<thead>
<tr>
<th>Group</th>
<th>No.</th>
<th>Age (mean)</th>
<th>Time after Tx (mean, months)</th>
<th>Rejections (no. patients)</th>
<th>Rejection treatment</th>
<th>CMV-reactivation* (no. patients)</th>
<th>Positive urine cultures (no. patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>13</td>
<td>42</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Transsectional</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTx patients</td>
<td>7</td>
<td>58</td>
<td>36, 5</td>
<td>2</td>
<td>corticosteroids</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Longitudinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTx patients</td>
<td>6</td>
<td>47</td>
<td>12</td>
<td>1</td>
<td>corticosteroids</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

CMV indicates cytomegalovirus; na, not applicable; RTx, renal transplantation; PCR, polymerase chain reaction.

*As defined by positive PCR or 4-fold rise in specific antibody titer.
heat inactivated FCS (Integro, Zaandam, The Netherlands), penicillin, and streptomycin. For the final 5 hours of culture, brefeldin A (Sigma) was added to the culture in a final concentration of 10 μg/mL. Cells were transferred to FACS tubes, fixed in 2 mL/tube FACS lysis solution (Becton Dickinson), permeabilized in 0.5 mL/tube FACS permeabilizing solution followed by (intracellular) staining with IFN-γ–FITC (Becton Dickinson) and CD69–PE (Becton Dickinson) and CD4–APC (Becton Dickinson) or CD8–APC (2I1006AX, clone UCHT-4, Imgen, ITK, Uithoorn, The Netherlands). Cells were washed in PBA and refixed in CellFix (Becton Dickinson) until flow cytometric analysis the following day. Flow cytometric analysis was performed using a FACS Calibur equipped with a 488-nm argon ion laser and a 635-nm red diode laser. Data files containing 50,000 events positive for CD4–APC or CD8–APC fluorescence within a lymphocyte gate were saved. Frequencies of CD69+IFN-γ+ cells within the CD4+ or CD8+ lymphocyte gate were determined using Cellquest software (Becton Dickinson) and designated CMV-specific CD4+ or CD8+ T-cell frequencies, respectively. Negative controls showed less than 0.05% of CD69+IFN-γ+ cells (data not shown).

**Peptides**

The HLA-A2 binding CMVpp65-derived peptide NLVPMVATV and the HLA-B7 binding CMVpp65-derived peptide TPRVTGGGA were purchased from the IHB-LUMC peptide synthesis library facility (Leiden, The Netherlands). The HIV Gag p17-derived peptide SLYNTVATL was kindly provided by Stefan Kostense (CLB, Amsterdam, The Netherlands). The peptides were generated by standard Fmoc techniques and purified by ether precipitation and HPLC techniques. The peptides were dissolved in dimethylsulfoxide (DMSO; Merck, Darmstadt, Germany) in a concentration of 5 mg/mL.

**Intracellular granzyme B and perforin staining**

Intracellular granzyme B and perforin staining was performed as described previously. In short, half a million PBMCs were stained with fluorescent-labeled conjugated mAbs to CD8 (Becton Dickinson), CD27 (Becton Dickinson), and CMV-tetrameric complexes, washed once with PBA, then fixed with 50 μL-buffered formaldehyde acetone solution and subsequently permeabilized by washing with 0.1% saponine 50 mM D-glucose. Cells were then incubated with antigranzyme B (CLB) and antiperforin antibodies (Becton Dickinson) and designated CMV-specific CD4+ or CD8+ T-cell frequencies, respectively. Negative controls showed less than 0.05% of CD69+IFN-γ+ cells (data not shown).

**CMV–polymerase chain reaction**

Quantitative polymerase chain reaction (PCR) was performed in EDTA whole blood samples as described for plasma or serum.

**Viral culture**

Viral culture was done by cocultivation of urine and human diploid fibroblasts. Microscopic examination for the appearance of CMV-specific cytopathologic effects was performed.

**Anti-CMV IgG**

Anti-CMV IgG was determined in serum using the AxSYM microparticle enzyme immunoassay (Abbott, Abbott Park, IL) according to the manufacturer’s instructions. Measurements were calibrated relative to a standard serum. Results are expressed as a ratio of the measurement to a standard serum (IgM).

**Statistical analysis**

Between-group analysis was performed using the nonparametric Mann-Whitney test. Within-group analysis was performed using the Wilcoxon signed rank test. Two-sided testing was done; P values lower than .05 were considered statistically significant.

---

**Results**

**Correlations of CMV-specific CD4+ and CD8+ T-cell frequencies in healthy individuals**

As previously demonstrated by us and others, CMV-specific CD4+ T cells can readily be detected in the circulation of healthy virus carriers using CMV antigen-induced IFN-γ production as read-out (Figure 1A). Likewise, CD8+ T cells could be visualized using the immunodominant CMV peptide in HLA-A2+ donors (Figure 1B). Frequencies of IFN-γ–producing cells within the CD8+ subset ranged between 0.18% and 0.80%. (Figure 2A). To directly visualize CMV-specific T cells, tetrameric HLA-A2.1/NLVPM-VATV complexes were generated. These complexes bound 0.54% to 3.77% of CD8+ T cells (Figures 1C, 2B). Accordingly, only on average 20% of the peptide-specific T cells in these chronic virus carriers were able to secrete IFN-γ in this short-term activation assay. Interestingly, in line with studies in mice, CD4 helper T-cell frequencies correlated with the percentage of CD8+ T cells secreting IFN-γ after peptide stimulation (Figure 1D, r = 0.7982, P < .05) but not with the amount of specific tetramer binding cells (data not shown).

---

**Figure 1. CMV-specific T-cell frequencies in healthy individuals.** (A) Dot plot of anti–IFN-γ–FITC fluorescence (x-axis, arbitrary units, log scale) versus CD69–PE fluorescence (y-axis, arbitrary units, log scale) of lymphocytes gated on positive CD4–APC fluorescence after incubation with CMV antigen. (B) Dot plot of anti–IFN-γ–FITC fluorescence (x-axis, arbitrary units, log scale) versus CD69–PE fluorescence (y-axis, arbitrary units, log scale) of lymphocytes gated on positive bright positive CD8–APC fluorescence after incubation with the HLA-A2–binding CMV-pp65 peptide NLVPM-VATV. (C) NLVPM-VATV-HLA-A2.1/tetramer APC fluorescence (‘tetramer,” x-axis, arbitrary units, log scale) versus CD8-PerC-P fluorescence (y-axis, arbitrary units, log scale) of lymphocytes gated on forward scatter and side scatter parameters. (D) Correlation of the frequency of IFN-γ–producing CMV-specific CD4+ T cells (x-axis, percentage of CD4+ T cells) and IFN-γ–producing HLA-A2+ restricted CMVpp65-specific CD8+ T cells (y-axis, percentage of CD8+ T cells) in HLA-A2+ CMV-seropositive healthy individuals (n = 7). IFN-γ–producing CMV-specific CD4+ T-cell frequencies correlate with IFN-γ–producing CMV-specific CD8+ T cells (r = 0.7928, P = .0480).
these CMV-specific CD8+ T cells. CCR7-CD27+ cells are represented in black, whereas CCR7+CD27- cells were virtually absent from the naïve T-cell subset (mean 1.5%).

To test whether in antigen-specific T cells expression of the various markers is comparable to that in the total population, CMV-specific T cells (Figure 4A) were analyzed for CD27, CCR7, and CD45RA coexpression. In all donors, CMV-specific CD8+ T cells were of the T EM type,9 that is, lacked expression of CCR7 (Figure 4B). Remarkably, however, with respect to the expression being expressed in a concordant way. The localization of CCR7- cells in CD8+ T-cell subsets defined by CD27 and CD45RA expression was determined (Figure 3C). Confirming recently published data,13 most (mean 97.0%, n = 4 healthy donors) effector-type CD45RA-CD27- T cells1 lacked CCR7. Additional analysis showed that most CCR7+ T cells also lacked CD28 and CD45R0 molecules (Figure 3D). However, an appreciable number of CCR7+ T cells appeared to be contained within the CD27+CD45RA-CD45R0+ population (mean 33.1%), CCR7+ T cells were virtually absent from the naïve T-cell subset (mean 1.5%).

Cell surface phenotype of CMV-specific CD8+ T cells in healthy individuals

On the basis of functional similarities of the subsets defined by CD27 and CCR7,9 one would expect that these molecules are
of CD27 and CD45RA molecules heterogeneous phenotypes were found. In most healthy donors, CMV-specific T cells appeared to be predominantly memory cells, that is, CD27⁻CD45RA⁻ (Figure 4C, right panel). However, in 3 donors mostly CD27⁻CD45RA⁺ effector cells were found (Figure 4C, left panel). In all donors presence or absence of CD27 strictly correlated with the expression of CD28 (data not shown). The phenotypes of CMV-specific T cells in individual donors were stable in time (data not shown).

Cytolytic mediators and natural killer cell receptors in CMV-specific T cells

The absence of CD27 corresponds within the expression of cytolytic mediators such as perforin and granzyme B. To establish if this phenomenon holds for virus-specific T cells, CMV-specific CD8⁺ T cells of a healthy donor with a predominant effector phenotype, and cells of one healthy donor with a predominant memory phenotype were analyzed for granzyme B expression by flow cytometry. Indeed, a high percentage of antigen-specific effector cells, that is, CD27⁻CCR7⁻CD45RA⁺, contained granzyme B, whereas only low numbers of CD27⁺CCR7⁻CD45RA⁺ cells contained the molecule (Figure 4D-E).

In analogy with findings on CD8⁺ T cells, we previously demonstrated⁹ that when CD8⁺ T cells differentiate toward the CD27⁻ effector type, T-cell expression of natural killer cell receptors (NKRs), both of the KIR and C-type lectin type, is acquired. Huard and Karlsson²⁰ postulated that repeated stimulation by antigen in vivo would up-regulate NKR expression. We therefore analyzed expression of CD94, NKB-1, CD158a, and CD158b on CD8⁺ T cells of healthy individuals who are consistently exposed to virus. Remarkably, irrespective of the CD27 phenotype of the CMV-specific T cells of the donors analyzed, the expression levels of the various NKRs were invariably low compared with the total CD8 population (Figure 5A-B).

Frequencies and properties of CMV-specific CD8⁺ T cells in renal transplant recipients

Frequencies of CMV-specific helper CD4⁺ T cells as measured by antigen-induced IFN-γ secretion did not differ significantly between healthy donors and recipients of renal transplants who were taking immunosuppressive drugs for an average of 36.5 months (median 0.20 versus 0.47%, P = .53, data not shown and Rentenaar et al³). However, the frequencies of virus-specific CD8⁺ T cells analyzed either by peptide-induced IFN-γ secretion or by direct visualization with HLA-A2.1–NLVPMMATV tetramers were significantly higher in the transplant recipients (P = .0082 respectively .0056, Figure 2A-B). Similar to CD8⁺ T cells in healthy donors approximately 20% of the antigen-specific CD8⁺ T cells were able to secrete IFN-γ in 6-hour stimulation assays (P = .558 between control individuals and transplant recipients, data not shown). In renal transplant recipients no significant correlation was found between helper cell frequencies and either IFN-γ-producing or number of CMV-specific CD8⁺ T cells (data not shown).

Phenotypic analyses showed that, in accordance with data obtained in healthy donors, CMV-specific CD8⁺ T cells in renal transplant recipients were CCR7⁻ and did not express NKRs (data not shown). Interestingly however, these cells were predominantly of the effector phenotype, that is, CD45RA⁺CD27⁻ (Figure 2C). In line with this surface phenotype, these cells expressed perforin (data not shown) and granzyme B (Figure 6A-B).

Repetitive antigenic stimulation induces loss of CD27

The transsectional findings and the data of Gillespie²¹ suggested that immunosuppressive therapy altered the CMV-specific CD8⁺ T-cell compartment in a quantitative and qualitative fashion. To test this directly, we investigated the effect of immunosuppressive therapy on the phenotype of CMV-specific CD8⁺ T cells in patients before and 12 months after transplantation. Mean frequencies of CMV-specific CD8⁺ T cells rose from 2.08% to 3.31% during this period (P = .313, not significant). Moreover, in 5 of 6 patients the percentage of CD27⁻ effector cells increased at the expense of the CD27⁺ memory cells. Interestingly, this change was most dramatic in a patient who had continuous positive urine cultures for CMV after transplantation (Figure 7A-B).

Discussion

The data presented in this paper establish a number of key features of CD8⁺ T cells involved in the control of persistent viruses, specifically CMV. CD4⁺ T cells are believed to be instrumental in the initiation of CD8⁺ T-cell expansion via the stimulation of...
availability of class II/CMV-peptide complexes that allow direct antigen presentation. The role of class II/CMV-peptide complexes in the induction of class I CMV-specific CD8+ T cells is unclear but possible effects of immunosuppressants on the differentiation of class I CD8+ T cells cannot be excluded. The reason for this paradox is unclear at this moment. Probably, antigens that persistently stimulate the immune system differ in their way of being presented and the context of presentation may have both direct and indirect effects on the expression of activation-regulating receptors. Elegant work from several groups has shown that CMV contains several genes that influence immune recognition. In this perspective it will be of interest to determine if other persisting viruses recruit memory and effector cells that also lack NKR.

In any case the data infer that control of CMV replication might be efficient because of lack of interference by NKR.
antigen-specific CD8+ T cells toward CD27- effector cells. It is unclear what specific signals drive differentiation of naive T cells into effector vis-a-vis memory CD8+ T cells. As discussed above, antigen may not be the sole factor in determining the CD8+ phenotype. Costimulatory signals delivered via cytokines or membrane-bound ligands may specifically regulate this process. In this respect it is interesting to note that both CD28 and CD27 costimulatory receptors augment effector functions and are down-modulated from the cell surface after interaction with their specific ligands.

Our data infer that effective immunosuppression of allospecific T-cell-mediated graft rejection the immune system is able to mount an adaptive response to persistent viruses such as CMV. In most healthy individuals, an equilibrium is achieved with a predominance of virus-activating memory-type CD8+ T cells. However, in response to viral and host factors, CD8 responses may be shifted toward effector-type cells. Indeed, in a number of our normal donors effector-type cells predominated. These individuals were healthy and did not have signs of viral replication in vivo. Interestingly, in elderly individuals the proportion of CD27− (and Rep and coworkers, unpublished observation, 1984), CD8−,CD11biight43 CD8+ T cells increases, suggesting that effector-type CD8+ T cells accumulate with age. This natural process may be accelerated in immunocompromised individuals who, due to pharmacotherapeutic immunosuppression, may be less fit to sufficiently repress viral replication. However, with adequate help from virus-specific CD4+ T cells these individuals may both quantitatively and qualitatively increase their effector CD8+ T-cell compartment thereby achieving a new equilibrium with the persisting virus. It follows that when this balance fails to establish, clinical disease may develop.

**Acknowledgments**

The authors thank the patients and volunteers for their blood donations, Dr F. Bemelman for assistance in collecting patient material, Frank van Diepen for excellent technical assistance, Dr R. Boom for development of the CMV-PCR, technicians from the Department of Clinical Virology for performing CMV-PCRs and cultures, and Drs Frank Miedema, Debbie van Baarle, and Michiel Betjes for critical reading of the manuscript. Dr Lijun Wu is thanked for providing the anti-CCR7 antibody and Dr Stefan Kostense for providing the HLA-A2/HIV-SLYNTVAL tetramers and peptide.

**References**

8. Azuma M, Cayabyab M, Phillips JH, Lanier LL. T lymphocytes have a phenotype of granzyme B+ T cells that accumulate with age. This natural process may be accelerated in immunocompromised individuals who, due to pharmacotherapeutic immunosuppression, may be less fit to sufficiently repress viral replication. However, with adequate help from virus-specific CD4+ T cells these individuals may both quantitatively and qualitatively increase their effector CD8+ T-cell compartment thereby achieving a new equilibrium with the persisting virus. It follows that when this balance fails to establish, clinical disease may develop.


Differentiation of cytomegalovirus-specific CD8+ T cells in healthy and immunosuppressed virus carriers

Laila E. Gamadia, Rob J. Rentenaar, Paul A. Baars, Ester B. M. Remmerswaal, Sugianto Surachno, Jan F. L. Weel, Mireille Toebes, Ton N. M. Schumacher, Ineke J. M. ten Berge and René A. W. van Lier